These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 2148131)
1. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Thow JC; Johnson AB; Marsden S; Taylor R; Home PD Diabet Med; 1990 Nov; 7(9):795-9. PubMed ID: 2148131 [TBL] [Abstract][Full Text] [Related]
2. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Thow JC; Johnson AB; Fulcher G; Home PD Diabet Med; 1990 Aug; 7(7):600-2. PubMed ID: 2146067 [TBL] [Abstract][Full Text] [Related]
3. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Henriksen JE; Vaag A; Hansen IR; Lauritzen M; Djurhuus MS; Beck-Nielsen H Diabet Med; 1991 Jun; 8(5):453-7. PubMed ID: 1830531 [TBL] [Abstract][Full Text] [Related]
4. Exercise augments the absorption of isophane (NPH) insulin. Thow JC; Johnson AB; Antsiferov M; Home PD Diabet Med; 1989; 6(4):342-5. PubMed ID: 2524341 [TBL] [Abstract][Full Text] [Related]
5. Effect of raising injection-site skin temperature on isophane (NPH) insulin crystal dissociation. Thow JC; Johnson AB; Antsiferov M; Home PD Diabetes Care; 1989 Jun; 12(6):432-4. PubMed ID: 2659303 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287 [TBL] [Abstract][Full Text] [Related]
8. Absorption kinetics of regular and isophane (NPH) insulin in the normal dog. Goeders LA; Esposito LA; Peterson ME Domest Anim Endocrinol; 1987 Jan; 4(1):43-50. PubMed ID: 3333933 [TBL] [Abstract][Full Text] [Related]
9. The contribution of intermediate-acting insulin preparations to daytime insulin treatment. Robert JJ; Chevenne D; Debray M Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136 [TBL] [Abstract][Full Text] [Related]
10. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810 [TBL] [Abstract][Full Text] [Related]
11. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
12. Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats. Wallace MS; Peterson ME; Nichols CE Domest Anim Endocrinol; 1990 Oct; 7(4):509-15. PubMed ID: 2261761 [TBL] [Abstract][Full Text] [Related]
13. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Jørgensen KH; Hansen AK; Buschard K Diabetes Res Clin Pract; 2000 Dec; 50(3):161-7. PubMed ID: 11106830 [TBL] [Abstract][Full Text] [Related]
14. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Ahmed AB; Home PD Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735 [TBL] [Abstract][Full Text] [Related]
15. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. Ahmed AB; Mallias J; Home PD Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002 [TBL] [Abstract][Full Text] [Related]
17. Absorption kinetics of short- and intermediate-acting insulins after jet injection with Medi-Jector II. Houtzagers CM; Berntzen PA; van der Stap H; Heine RJ; van der Veen EA Diabetes Care; 1988 Oct; 11(9):739-42. PubMed ID: 3066607 [No Abstract] [Full Text] [Related]
18. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Radziuk J; Pye S; Bradley B; Braaten J; Vignati L; Roach P; Bowsher R; DiMarchi R; Chance R Diabetologia; 1998 Jan; 41(1):116-20. PubMed ID: 9498640 [TBL] [Abstract][Full Text] [Related]
19. Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection. Krug EI; DeRiso L; Tedesco MB; Rao H; Korytkowski MT Diabetes Care; 2001 Sep; 24(9):1694-5. PubMed ID: 11522727 [No Abstract] [Full Text] [Related]
20. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin. Olsson PO; Hans A; Henning VS Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]